Morgan Stanley lowered the firm’s price target on Halozyme (HALO) to $93 from $96 and keeps an Overweight rating on the shares. Halozyme reported “solid” Q1 results, 2026-2028 guidance was reiterated and a new share repurchase program was announced, the analyst noted.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HALO:
- Halozyme Maintained at Buy as Strong Execution and Shareholder Returns Offset Modest Price Target Trim to $93
- Analyst Reiterates Buy on Halozyme, Citing Underappreciated Growth and Maintaining $96 Price Target
- Halozyme reports Q1 non-GAAP EPS $1.60, consensus $1.52
- Halozyme still sees 2026 non-GAAP EPS $7.75 to $8.25, consensus $8.09
- HALO Earnings this Week: How Will it Perform?